Verisante Technology Inc. V.VRS

RE:Previous Valuations

[basherbuster]

I would like to give more input, but my time does not allow the research involved. However, there may be something brewing in the mix of news related.

https://www.verisante.com/news/114/verisante-technology-inc-announces-study-on-nasopharnygeal-cancer-in-china-/

“The Verisante Core™ for nasopharyngeal cancer detection has the potential to significantly improve patient outcomes,” said Dr. Zeng, who is also an associate professor of dermatology and skin science at the University of British Columbia in addition to his work at the BC Cancer Agency. “Our collaboration with the Fujian Normal University in China is an important step in testing the technology on real patients in a clinical setting.”

Nasopharyngeal carcinoma is the most common cancer found in the nasopharynx (the upper part of the throat behind the nose). It is fairly rare in North America, but much more common in Southern China and North Africa and was the seventh most fatal cancer in Hong Kong in 2011. The five-year survival rate for people diagnosed with nasopharyngeal cancer is 72 percent if found early, decreasing to only 38 percent if found at a later stage.

“We are pleased to continue our partnership with the BC Cancer Agency and to collaborate with a reputed research organization like Fujian Normal University in China,” said Thomas Braun, President and CEO. “While the Company continues to work closely with our exclusive distributors to support the sales and marketing efforts of our skin cancer detection device, Aura™, we are also making good progress with Verisante Core™. Adding the nasopharyngeal application and collaboration with China nicely rounds out our continuing portfolio of studies on applications for the Core™, which will be our next product to market. There continues to be high level interest in developing applications for the Core™ in China and throughout the Asian markets.”

In addition to this new nasopharyngeal collaboration, the clinical studies involving lung cancer and colon cancer using Verisante Core™, the Company’s endoscopic Raman technology, continue.

I have been hanging in way too long.

Good luck longs